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Abstract
Incipient Alzheimer’s Disease (AD) is characterized by a slow onset of clinical
symptoms, with pathological brain changes starting several years earlier. Consequently,
it is necessary to first understand and differentiate age-related changes in brain regions
in the absence of disease, and then to support early and accurate AD diagnosis.
However, there is poor understanding of the initial stage of AD; seemingly healthy
elderly brains lose matter in regions related to AD, but similar changes can also be
found in non-demented subjects having mild cognitive impairment (MCI). By using a
Linear Mixed Effects approach, we modelled the change of 166 Magnetic Resonance
Imaging (MRI)-based biomarkers available at a 5-year follow up on healthy elderly
control (HC, n=46) subjects. We hypothesized that, by identifying their significant
variant (vr) and quasi-variant (qvr) brain regions over time, it would be possible to
obtain an age-based null model, which would characterize their normal atrophy and
growth patterns as well as the correlation between these two regions. By using the null
model on those subjects who had been clinically diagnosed as HC (n=161), MCI
(n=209) and AD (n=331), normal age-related changes were estimated and deviation
scores (residuals) from the observed MRI-based biomarkers were computed. Subject
classification, as well as the early prediction of conversion to MCI and AD, were
addressed through residual-based Support Vector Machines (SVM) modelling. We found
reductions in most cortical volumes and thicknesses (with evident gender differences) as
well as in sub-cortical regions, including greater atrophy in the hippocampus. The
average accuracies (ACC) recorded for men and women were: AD-HC: 94.11%,
MCI-HC: 83.77% and MCI converted to AD (cAD)-MCI non-converter (sMCI): 76.72%.
Likewise, as compared to standard clinical diagnosis methods, SVM classifiers predicted
the conversion of cAD to be 1.9 years earlier for females (ACC:72.5%) and 1.4 years
earlier for males (ACC:69.0%).
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Introduction 1
AD is a disease with both brain pathological processes and clinical decline occurring 2
gradually, with dementia representing the last stage of many years of accumulation of 3
these pathological changes. Changes begin several years before the onset of clinical 4
symptoms and there is strong supporting evidence that it is related to the early 5
abnormal production of   amyloid (A ) peptide in the Cerebrospinal fluid (CSF).    6
amyloidosis and the increase of CSF- ⌧ protein precede neuronal dysfunction and 7
neurodegeneration; and all of these precede cognitive changes and correlate with clinical 8
symptom severity [1, 2]. Neurodegeneration begins with a typical pattern of early 9
neurofibrillary tangles in medial temporal lobe structures, mainly entorhinal cortex and 10
hippocampus, and subsequently extending throughout most of the temporal lobe and 11
the posterior cingulate. Finally, this pattern involves extensive cortical regions, 12
especially parietal, prefrontal and orbitofrontal; and in an advance stage, change in 13
several brain structures correlate closely with changes in cognitive [3, 4]. In addition to 14
the foregoing, it is known that the apolipoprotein E (APOE) ✏4 allele is the most 15
prevalent genetic risk factor for AD [5]. Carriers of ✏4 attain AD at an earlier age than 16
non-carriers [1,5]; this may be due to ✏4 being involved in early A  plaque concentration 17
and neuro-degeneration. However, in spite of these findings, it is important to be clear 18
that ✏4 carriers merely inherit an increased risk of developing the disease, but not all 19
people with AD are ✏4 carriers, and not all ✏4 carriers will develop the disease. 20
Indeed, to understand the specific effects of AD on brain structures, it is important 21
to study and differentiate their age-related changes in the absence of disease. Ageing 22
causes changes at all levels, from molecular to morphological, in the brain which include 23
shrinking. Studies have demonstrated that seemingly healthy subjects lose brain matter 24
over time and brain age-related changes and function are not uniform across the whole 25
brain or over subjects. The volume of the brain decreases with age at a rate of 26
approximately 0.2–0.5% per year [6] and this rate might be even greater over the age of 27
70 [7]. Regionally, ageing-related atrophy has been observed across many of the cortical 28
regions [6,8,9] with a prominent decline in the prefrontal cortex and the slight decline of 29
the temporal cortex and parahippocampal cortex [8]. Decline has been also found in 30
several subcortical structures including the caudate nucleus, amygdala, cerebellum and 31
hippocampus [6, 9], the latter being the most studied structure, with annual atrophy 32
rate of about 2.0% [6]. Studies on cross-sectional and longitudinal MRI have found 33
significant correlations between gender and cortical and subcortical regions, but there 34
are inconsistencies between the results [8, 9]. Finally, another factor to consider with 35
regard to the effects of ageing on the brain and cognition is the influence of 36
socio-demographic characteristics. Both higher levels of education or occupational 37
attainment may act as a protective factor. For example, studies have found that higher 38
levels of education may increase the brain reserve, leading to larger brain structures, 39
which can help to counter the effects of brain atrophy [9, 10]. 40
However, many of these age-related changes are shared by neurodegenerative 41
diseases. Some studies have found that cognitively normal elderly (HC) have A  42
deposition in the brain with similar levels of the substances observed in subjects with 43
dementia due to AD [11]. Similarly, despite an increase in ⌧ protein having been seen in 44
AD as compared to HC, ⌧ deposition is found in other neurodegenerative diseases 45
referred to as tauopathies [12]. At the macroscopic level, ageing has an effect on brain 46
morphology with atrophy caused by dendritic pruning and loss of synapses and neurons. 47
Part of this atrophy occurs in areas vulnerable to AD, while other changes have been 48
observed in areas less characteristic of early-stage AD [6,8, 9]. Because of the shared 49
biochemical and morphological characteristics, it must be pointed out that it is a 50
complex task to discriminate some of these age-related changes in healthy elderly 51
subjects from subjects affected with early stage of AD. 52
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In clinical practice, neuropsychological tests such as, the Clinical Dementia Rating 53
(CDR) [13], the Mini-Mental Examination Score (MMSE) [14] and the Alzheimer’s 54
Disease Assessment Scale cognitive subscale are used to monitor AD progression or 55
treatment efficacy. However, although these tests unquestionably reflect an important 56
aspect of disease progression (i.e. functional impairment), they also have several 57
limitations such as relatively low specificity [15] and reliability [16]. During the past few 58
years, there has been a considerable effort to identify additional biomarkers as early 59
indicators of pathological changes to improve the accuracy of the clinical diagnosis of 60
possible/probable AD and the prediction of disease progression from Mild Cognitive 61
Impairment (MCI) which is a symptomatic predementia phase of AD [17]. In spite of 62
CSF-A  and CSF-⌧ have been suggested as the most informative AD biomarkers [18]; 63
several studies also suggested their combination with other features types, such as 64
Magnetic Resonance Imaging (MRI)-based biomarkers, to increase early prediction 65
accuracy [19]. Currently, neuroimaging and specifically structural MRI biomarkers 66
support earlier and more precise diagnosis and measurement of progression. MRI 67
Biomarkers of atrophy of medial temporal regions have been validated for early 68
diagnosis of subjects at the MCI stage. Furthermore, MRI images used to measure rates 69
of whole-brain and hippocampal region are considered powerful markers of progression 70
of neurodegeneration being used as outcomes in clinical trials [4]. 71
Alternatively, studies based on high dimensional methods have approached the 72
HC/MCI/AD early prediction problem of automatically classifying brain regions and 73
subjects from structural MRI-based biomarkers. These biomarkers allow the careful 74
examination of morphological changes and their correlation with the progression of 75
cognitive impairment. Multivariate techniques such as Orthogonal Partial Least Squares 76
(OPLS), Support Vector Machine (SVM) and Relevance Vector Machine (RVM), among 77
others, have enabled the correlation and variance of these biomarkers to be evaluated in 78
a more easily interpreted way and with greater statistical power as compared to 79
univariate approaches. Likewise, MRI biomarkers have been used in combination with 80
other types of biomarkers, such as Positron Emission Tomography (PET)-based 81
features, CSF-based biomarkers, Genetic-based biomarkers and socio-demographic and 82
neuropsychological features to improve early diagnosis performance. Recent studies have 83
proposed an age estimation framework by training RVM for regression (RVR) from 84
MRI-based biomarkers of healthy subjects, which was used to estimate the age of MCI 85
and AD subjects and to recognize faster brain atrophy [20,21] and to predict the 86
conversion from MCI to AD [22]. Other studies have proposed methods to calculate an 87
MRI-based AD severity index from cross-sectional [23] and longitudinal studies [24], 88
where multivatiate models based on OPLSR were built from HC and AD subject data. 89
Models were applied to MCI subjects for early prediction of conversion to AD through 90
subject classification as either healthy control-like or as AD-like. Besides the 91
above-mentioned methods, studies have also applied SVM algorithms to improve 92
prediction quality by selecting the most significant brain structures or other feature 93
types in HC, MCI and AD subjects [3, 19, 25–29]; and to discriminate between these 94
subject groups [3, 19, 25–28,30, 31]. However, in spite of applied multivariate techniques 95
and the features used, all these studies are focused mainly on three classification 96
experiments : (1) HC vs AD, (2) HC vs MCI and (3) MCI vs AD; where the last one is 97
mainly directed at discriminating between the stable MCI (sMCI, MCI who had not 98
converted to AD) vs converted to AD (cAD, subjects who had converted to AD). For 99
HC vs AD, the methods mentioned achieved high accuracy values (up to 94.9% 100
sensitivity and 96.33% specificity); and from 78% to 85% on MCI vs AD. However, for 101
the detection of prodromal AD (sMCI vs cAD), the sensitivity is substantially lower 102
(below 60%) for most methods. 103
In this study, we aimed to characterize the age-related changes in brain structures 104
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and to identify the variant (vr) and quasi-variant (qvr) MRI biomarkers to build 105
ageing-based null models. Null models were built from identified HC subjects (n=46) 106
with a normal CSF-profile. Most importantly, we addressed the HC/MCI/AD subject 107
classification and the early prediction of conversion to AD, by using these null models to 108
estimate the age-related values of vr and qvr MRI biomarkers for longitudinal data of 109
HC (n=161), MCI (n=209) and AD (n=331) subjects. Residuals were then calculated 110
as deviation scores of observed MRI-based biomarkers from estimated normal 111
MRI-based biomarkers. Support vector machines (SVM) were used to build 112
residual-based classifiers for three experiments: MCI vs HC, AD vs MCI and AD vs HC. 113
The advancement for early disease prediction was calculated as the number of years that 114
the proposed method leads in predicting the last known subject diagnostic. Data used 115
in this study was obtained from the Alzheimer’s Disease Neuroimaging Initiative 116
(ADNI) study (adni.loni.usc.edu). 117
Data 118
ADNI cohorts 119
The ADNI was launched in 2003 as a public-private partnership, led by Principal 120
Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test 121
whether serial MRI, PET, other biological markers, and clinical and neuropsychological 122
assessment can be combined to measure the progression of MCI and AD. For up-to-date 123
information, see www.adni-info.org. 124
The complete ADNI project enrolled 819 adult subjects, aged 55—90 years, and 125
recruited from over 50 sites across the United States and Canada. These subjects met 126
entry criteria for a clinical diagnostic at baseline (see S1 Appendix ) of late MCI (LMCI, 127
n=398), early probable AD (n=193) and control normal (CN, n=229) [32]. ADNI has 128
been used by many number of publications focused on the characterization of age-related 129
brain changes [6, 33] and the early prediction of conversion to AD [19,23,31,34,35]; a 130
recent review has been published by Weiner and colleagues in Alzheimer & Dementia 131
journal [36]. Details about the procedures for selection of participants and the full study 132
protocol have been presented in [16,37]. Also, details of the acquisition of structural 133
MRIs of the participants can be found in ADNI project site (adni.loni.usc.edu). 134
CSF biomarkers. 135
The ADNI CSF-based biomarkers were measured for A  1 to 42 peptide (CSF-A ), 136
total tau (CSF-⌧) and ⌧ phosphorylated at the theorine 181 P-⌧181P concentrations 137
using the xMAP platform (Luminex Corp, Austin, Texas) and INNO-BIA AlzBio3 138
research-use-only reagents. Biomarkers analysis applied by ADNI are described in detail 139
at http://adni.loni.usc.edu/methods/biomarker-analysis/. CSF biomarkers set 140
was conformed by CSF-A  and CSF-⌧ , in pg/mL. 141
MRI-based Biomarkers. 142
MRI-based biomarkers used in this study correspond to measured of neuro-degeneration 143
available in ADNI at 5 years follow-up. These biomarkers were obtained with the 144
FreeSurfer image analysis suite (version 5.1.0) developed by Martinos Center for 145
Biomedical Imaging and freely available at the ”Freesurfer wiki site” 146
(http://surfer.nmr.mgh.harvard.edu/fswiki). FreeSurfer has been used in several 147
studies dedicated to automatically obtaining MRI-based measures from whole brain or 148
specific regions to sucessfully predict the early conversion from MCI to AD 149
subjects [19, 23, 24, 31,34, 38, 39]. Technical details of the FreeSurfer processing pipeline 150
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have been described in prior publications [40, 41]. Biomarkers with missing values for 151
most samples were discarded. Likewise, we only included the ones correctly processed 152
and available for at least two time points. In this sense, we included an unbalanced 153
longitudinal data of 166 longitudinal MRI-based biomarkers measured at multiple time 154
points: baseline, 6, 12, 18, 24, 36, 48 and 60 months. These biomarkers correspond to 155
cortical volume (CV), cortical thickness average (TA) and the volume estimates of a 156
wide range of sub-cortical structures (SV). 157
Subjects and inclusion criteria. 158
Participants were selected from original ADNI study if they met the following criteria 159
(at the time of the study, April, 2015): (1) Had all selected longitudinal MRI images 160
correctly processed (2) Had completed demographic and neuropsychological data and 161
were clinically diagnosed at each visitation. In total, longitudinal data of 747 subjects 162
(215 CN, 366 LMCI and 166 AD) were studied. Demographic details of the studied 163
cohort are given in Table in S1 Table. Summaries are grouped by gender and 164
correspond to baseline stage. It should be noted that just 164 women and 236 men have 165
available measures of CSF-based biomarkers. 166
Methods 167
This study was divided into three main stages: (1) Subject classification, (2) Building 168
the ageing-based null models, and (3) Residuals-based early prediction of conversion to 169
MCI/AD and HC/MCI/AD classification with SVM classifiers. Fig 1 illustrates a 170
schematic diagram of the proposed framework. 171
Fig 1. Proposed framework.
(A) HC subjects with normal CSF profile are identified from cutoff values calculated
from CSF biomarkers distributions. (B) Longitudinal ROIs of these subjects are
modelled using LME approach, variant (vr) and quasi-variant (qvr) ROIs and
Y-intercepts (y0) ROIs values are identified and then null models for both genders are
built from these values by applying multivariate modelling. (C) qvr ROIs values of new
HC, MCI and AD subjects are used within null models to infer the y0 values of vr ROIs.
Estimated ROIs values (yˆ) at different ages are estimated by linear regression by using
y0 and   coefficients of age and education. Residuals are calculated as the difference
y   yˆ; and finally, SVM classifiers are trained for subject classification and addressing
the early diagnosis problem: HC vs MCI, MCI vs. AD and HC vs AD. The full
workflow of last two stages is applied separately for each gender.
Classification of Subjects. 172
Since the diagnosis of MCI and AD is progressive, in addition to ADNI clinical 173
assessment established at every visitation (dxage), we aim to control the last ADNI 174
clinical diagnosis of each subject at time of this study, by building a time-invariant 175
diagnosis variable (dxlast). This variable labels subjects according the following classes: 176
(1) stable HC (sHC), (2) stable MCI (sMCI), (3) converted to MCI (cMCI), (4)stable 177
AD (sAD) and (5) converted to AD (cAD). Because previous studies have found ADNI 178
participants with abnormal concentrations of CSF-based biomarkers even in healthy 179
elderly subjects [18,42], we decided to study the subjects with available CSF data (see 180
Table in S1 Table) and to discriminate the ones with normal CSF-profile from the ones 181
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with abnormal concentrations. For this propose, we investigated the cut-off values 182
previously established by [18] (CSF-A  : 192pg/ml, CSF-⌧ : 93pg/ml) [18] from their 183
study with ADNI-independent autopsy-based samples, on our samples at long-term 184
follow-up times (84 months). As many of these subjects have more than one 185
measurement available for both CSF-based biomarkers, the normal or abnormal profile 186
was evaluated for all observations. In this way, we expected to classify these subjects 187
through the other time-invariant feature (dxcsf ), which combines their dxlast state and 188
their CSF profile. Table 1 gives a brief description of all diagnosis variables used in this 189
study. Once the subjects were characterized according to dxlast and dxcsf , two cohorts 190
were established: (1) The null model cohort, integrated by the stable HC subjects with 191
normal CSF profile (normal-HCcsf); and (2) The early prediction cohort, integrated by 192
the remaining subjects who did not meet the previous condition. 193
Table 1. Classification results with current diagnostic.
Source Diagnostic variable Class Class description
ADNI dxbl CN Control normal at baseline
LMCI Late MCI at baseline
AD Early probable AD at baseline
dxage NL Subjects diagnosed as stable normal at current visitation
NL to MCI Subjects diagnosed as MCI at current visit who previously were NL
NL to Dementia Subjects diagnosed as dementia due to AD at current visit who previously were NL
MCI Subjects diagnosed as stable MCI at current visit who previously were also MCI
MCI to Dementia Subjects diagnosed as dementia due to AD at current visit who previously were MCI
Dementia Subjects diagnosed as stable dementia due to AD at current visit who previously were also
MCI
Our study dxlast sHC Subjects labelled as HC who remained like HC in all follow-up visits (who did not become
MCI or AD)
sMCI the MCI subject who did not become AD
cMCI Subjects initially labelled as HC who subsequently have converted to MCI
sAD Subjects who remained like probable or possible AD all the follow-up visits
cAD Subjects labelled as HC or MCI who subsequently have converted to probable or possible AD
dxcsf normal-HCcsf sHC subjects with normal CSF profile
abnormal-HCcsf sHC subjects with abnormal CSF profile
normal-MCIcsf sMCI and cMCI subjects with normal CSF profile
abnormal-MCIcsf sMCI and cMCI subjects with abnormal CSF profile
normal-ADcsf sAD and cAD subjects with normal CSF profile
abnormal-ADcsf sAD and cAD subjects with abnormal CSF profile
Building the ageing-based null models 194
In this stage, we analyzed data from the null model cohort. Every MRI-based biomarker 195
of the normal-HCcsf group was standardized to have zero mean and unit variance. Here, 196
we also refer to an MRI-based biomarker as a Region of Interest (ROI) when we refer to 197
the modelling process. 198
Modelling temporal change in ROIs. 199
To visualize the between-subject and within-group variabilities on normal-HCcsf, ROIs 200
were represented by quartiles. The change in cortical and subcortical brain regions over 201
5 years was calculated by applying the LME approach for every ROI. The subject age 202
(age) at each observation and the years of education (educ) were included as covariates 203
in all models. Because we hypothesize that there are important individual-level effects 204
and believe that subjects have similar rates of change over time, we fitted random 205
intercepts LME models. In this type of model, the measured value of ROI r defined as 206
yij is assumed to have a set of parameters  , fixed across subjects. In addition, for each 207
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individual i, a set of random parameters  i is assigned that models the deviation from 208
the fixed effect  . For i = 1, ..., n, each model reads as follows: 209
yrij = Xij 
r + Zij 
r
i + ✏
r
ij (1)
where, yrij is the standardized value of ROI r measured for the i
th subject in the jth 210
observation; i = 1, ..., n subjects, j = 1, ..., ni available observations for subject i and 211
r = 1, ..., nr, nr = 166 ROIs. Xij is a ni x p design matrix, where p is the number of 212
covariates (age, educ and the constant term of 1’s) on the jth observation of ith subject. 213
 r is the p x 1 vector of unknown fixed effects or regressor’s coefficients, which are:  r1 214
(coefficient for constant term or Intercept),  ra (coefficient for age) and  
r
e (coefficient 215
for educ). Zij is a known design matrix of size ni x q, where q is the number of random 216
effects for the jth observation of subject i.  ri is the q ⇥ 1 vector of unknown random 217
effects coefficients ⇠ Nq(0, ) for subject i measured for ROI r. ✏rij is the nix1 residual 218
vector of errors ⇠ Nni(0, 2 i) for the jth observation in subject i measured for ROI k. 219
 is the q ⇥ q covariance matrix for the random effects. 0, 2 i is the ni x ni covariance 220
matrix for the errors in subject i. 221
LME modelling was performed using the lme4 package available for R [43]. See S1 222
Appendix for further detail of the specific LME approach. 223
Identification of variant and quasi-variant ROIs. 224
The predictor estimates of LME models were interpreted the same way as the 225
coefficients from a traditional regression. For instance, a one year increase in the 226
regressor age corresponded to the effect of age ( a) increase or decrease in the outcome. 227
Taking into account the  a’s, we classified as variant (vr) ROIs the ones that had both 228
an annual change greater than 1% on ROI standard deviation and a significant change 229
at p-values  0.05. The ROIs with annual change less than or equal to 1% were 230
considered as quasi-variant (qvr), where all of these did not have a significant change. 231
Inference of variant ROIs y-intercept values from quasi-variant ROIs. 232
The Y-intercept value (y0) from each ROI, which represents the subject-specific ROIs 233
measure at basal stage (age = 0), was directly obtained from all LME models. We 234
assumed that for healthy elderly people, the qvr ROIs values remains basically the same 235
along time, even at basal stage, which is not true in the vr. We also assumed there are 236
a strong correlation between the y0 set of both ROI types. Therefore, we built the HC 237
null model based on the Partial Least Squares Regression (PLSR) algorithm [44] to infer 238
the set of y0’s for vr ROIs in function of the set of y0’s for qvr ROIs. PLSR is a linear 239
algorithm particularly useful to analyze data with strongly collinear (correlated), noisy, 240
and numerous predictors variables, and also simultaneously model several response 241
variables [45]. There are several algorithms proposed to implement the PLSR model. In 242
this study, we use the kernel algorithm [46] available in the pls package available for 243
R [47]. To determine the optimal number of components to take into account, it was 244
used leave-one-out (LOO) cross-validation method available in this package. LOO 245
calculates potential models excluding one observation at a time. See S1 Appendix for a 246
short PLSR description. 247
Early disease prediction based on residuals. 248
In this stage, we addressed the subject classification and early disease prediction 249
problems using data from the early prediction cohort (HC, MCI and AD), unused in the 250
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previous stage. ROIs of these subjects were standardized according to the mean and 251
standard deviation of the null model cohort. 252
Inference of age-associated ROIs values for new subjects. 253
For each subject, the y0’s of vr ROIs were inferred from the y0’s of qvr ROIs using the 254
same PLSR model described in previous section. Once the y0 set for both ROIs types 255
was completed, we used these values in combination with the vector of coefficients  , see 256
Eq (1) and the observed covariates (age and educ), to infer the expected values of each 257
ROI (yˆij) according to Eq (2). Here,the inferred value represents the value that should 258
measure the ROI at age 6= 0 whether the subject is healthy or not. 259
yˆrij = yˆ0
r
i + (Xij 
r) (2)
where yˆrij represents the inferred or predicted value of the r
th ROI variant on the jth 260
observation for the ith subject. Xij is the design matrix with observed covariates at 261
age 6= 0 without the constant term.  r is the vector of calculated fixed effects of ROI r 262
obtained from its LME model, according Eq (1). 263
Computing the residuals of variant ROIs. 264
In order to get a meaningful deviation value of ROIs from an inferred healthy 265
subject-specific trend, the difference between the estimated (yˆ) and the true (yˆ) ROIs 266
values, here called residual (e), was computed. The residuals erij for each ROI were 267
calculated as following: 268
erij = y
r
ij   yˆrij (3)
where yij and yˆij are the observed and inferred values, respectively, for each ROI r 269
measured on the ith subject in the jth observation. The e’s for all ROIs were stored in a 270
matrix E. 271
In S1 Appendix we describe a hypothetical example of how we have used the LME 272
and PLSR approaches to infer the ROI values at basal stage and over time; and finally, 273
the residuals. 274
Diagnosis prediction using Support Vector Machines. 275
In this stage, we used the matrix of residuals E to address two problems. The first one 276
was focused on the subject classification, where the vector of class labels, used as the 277
outcome, was the diagnostics at the time of the visit, dxage (Table 1). The second 278
problem was the early disease prediction, here, we trained a classifier that predicts the 279
future diagnosis of the subjects given their current clinical tests, i.e. what is the 280
expected diagnostic of the subject some years after the current visit. The vector of class 281
labels used to train this classifier was dxlast (Table 1). In this case, as the feature set 282
used was obtained in previous visits of the subject, the classifier learns to predict the 283
future outcome of a subject, given his present state. 284
For both problems, we performed three experiments focused on the binary 285
classification problems: (1) HC vs AD, (2) HC vs MCI and (3) MCI vs AD. The MCI vs 286
AD experiment in the early prediction problem was focused on addressing the problem 287
of prodromal stage of AD, by comparing the sMCI (stable MCI over all visitations) with 288
the subject initially diagnosed as MCI who became to AD over time (cAD). Likewise, 289
for each problem, two configurations of the feature set have been tested. Let Ev be the 290
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subset of matrix E where only the columns of either the vr ROIs or the qvr ROIs whose 291
residuals are different from zero were included. The first feature set used in each 292
experiment, F1, included the residuals from matrix Ev plus the age (age of the subject 293
at the time of the visit). The second feature set used, F2, includes the information in F1 294
together with the results from the CDR global score (CDRGLOBAL) and MMSE tests. 295
The goal of testing two training sets was to assess the influence of the neuropsychological 296
tests in the quality of diagnostic as opposed to the use of ROI residuals with age only. 297
The classification method used to carry out each experiment is a Support Vector 298
Machine (SVM), configured with a Gaussian radial kernel and a misclassification cost 299
parameter C = 1. Each experiment has been evaluated using a ten-fold cross validation 300
with a specific constraint: as ADNI is a longitudinal database, there may be multiple 301
samples per subject (multiple visits). The subjects were assigned to either the training 302
or the test subsets, in order to perform a fair evaluation. On each cross validation run, 303
60% of the subjects weren assigned to the training subset and the remaining 40% to the 304
test subset. 305
Because, it is known that the rate of atrophy increases with age, for studying the 306
development of our method for early disease prediction, SVM classifiers were built on 307
age groups. The ADNI data used to evaluate the classification for males and females are 308
summarized in tables in S2 Table and S3 Table, respectively. These tables provide 309
demographic information and the number of measurements and diagnoses by each age 310
group. 311
Since previous studies have suggested that there are gender differences in brain 312
atrophy with aging [8, 9, 48–50], the full workflow in building null models and early 313
diagnostic from SVM models was applied separately for each gender. 314
Results 315
Healthy elderly subjects with normal CSF profile 316
Analysis of CSF-A  and CSF-⌧ biomarkers showed us that their distributions were not 317
normal for all diagnosis groups (see figure in S2 Fig). A bimodal distribution was 318
observed in CSF-A  levels within each diagnosis group. CSF-⌧ values in CN group 319
showed a unimodal normal distribution. We confirmed cut-off values determined by [18], 320
classifying as normal the CSF profile of subjects who fulfilled both conditions: 321
CSF-A  >= 192pg/ml and CSF-⌧  93pg/ml. From CSF profiles, we identified 46 322
normal-HCcsf, 33 normal-MCIcsf, 11 normal-ADcsf, 63 abnormal-HCcsf, 75 323
abnormal-MCIcsf and 172 non-ADcsf subjects. Figure in S3 Fig shows CSF-⌧ 324
concentration versus CSF-A  concentration for these six groups, where the blue dots 325
represent the HC subjects with normal CSF profile used to build the null models for 326
men and women. Furthermore, in figure 2 is shown the last available measurements of 327
CSF biomarkers concentrations for the studied ADNI subjects grouped according dxcsf . 328
An increase in ⌧ values was observed when comparing normal-HCcsf and subjects with 329
abnormal CSF-profile, and when comparing abnormal-HCcsf with MCI and AD subjects 330
with abnormal profile. With respect to A  levels, we observed a reduction of levels 331
when comparing normal-HCcsf with abnormal-HCcsf and the remaining groups with 332
abnormal profile. 333
Fig 2. Boxplot of CSF biomarkers concentrations for dxcsf diagnostic
groups.
(a) CSF-A 1  42; and (b) CSF-⌧ .
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In total, 226 samples were available for the 46 normal-HCcsf subjects (males: 22, 334
females: 24). Table 2 provides their demographic information at baseline. Age, 335
education and MMSE scores were similar across gender, but CSF concentrations and 336
CDRGLOBAL were different between men and women. Furthermore, only three 337
subjects (2 males and 1 female) were carriers of APOE-✏4 at allele 1. More detail of 338
demographic and cognitive measures are given in S1 Appendix. 339
Table 2. Baseline statistical descriptors of HC subjects selected for null models
building.
Female Male
N = 24 N = 22
age 71.2 75.1 77.7 (74.7± 5.3) 70.4 71.8 74.0 (72.7± 6.0)
education 65.0 70.0 80.0 (0.73± 0.09) 70.0 82.5 90.0 (0.81±0.15)
APOE-✏4
0 95.8% 2324 90.9% 2022
1 4.2% 124 9.1% 222
MMSE 29.0 29.0 30.0 (29.25± 0.67) 28.0 29.0 30.0 (28.54± 1.50)
CDRGLOBAL
0 100% 2424 82% 1822
0.5 0% 024 18% 422
CSF-A  234.9 248.5 256.0 (247.23± 20.14) 235.0 257.9 268.2 (253.22± 21.69)
CSF-⌧ 47.9 55.260.9 (55.41± 15.10) 47.0 59.9 73.8 (59.84± 16.83)
a b c represent the lower quartile a, the median b, and the upper quartile c for
continuous variables. x± s represents X¯ ± 1 SD.
Ageing-based variant (vr) and quasi-variant (qvr) ROIs. 340
A study of within-subject and between-subject variabilities, using the box plots 341
representation, showed us that there are significant between-subject variability and 342
strong gender effect for several ROIs; for example, the left hippocampal volume (see 343
Figure in S4 Fig). However, for other ROIs their change was not very evident. From 344
LME modelling, we identified 97 vr ROIs for males and 109 vr ROIs for females. 345
Regarding quasi-variant ROIs, we found 69 qvr for males and 57 qvr for females. The 346
figure in S5 Fig shows examples of fitted LME models for both types of ROIs within 347
each gender. In a similar way to these examples, the  a’s of the remaining vr ROIs were 348
observed as being close to zero, but for qvr ROIs, their slopes were not. The figure in 349
S6 Fig shows the summary of ageing-associated differences of biomarkers in men and 350
women. The results suggest important ageing-related reductions in neocortical and 351
subcortical regions and ventricular expansion, with several gender-specific significances. 352
Reductions are observed in the most of cortical volumes and cortical thickness, where 353
men and women showed a similar degree of global thinning. Some of these regions 354
showed prominent atrophy while others showed a more conservative change; for 355
example, the entorhinal volume was observed to be significantly reduced in females but 356
not in males. In relation to the subcortical regions, we observed several gender-specific 357
differences, some of these are: significant volumetric reductions in both hemispheres of 358
hippocampal volume for both males and females; ventricular expansion in both genders, 359
but just the change of fourth ventricle volume was not significant; the volume of the 360
optic chiasm region was significantly increased in females, but it was not significant in 361
males; a reduction in amygdala volume was significant in both hemispheres of the male 362
brain but it was not significant in females; and, in general, the volume of bilateral 363
corpus callosum regions are observed as thinned, but without significant differences 364
between the genders. 365
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Subject classification based on ROI residuals 366
The table in S4 Fig shows the average prediction accuracy (ACC), sensitivity (SEN) 367
and specificity (SPE) of the test for both the F1 and F2 training set configurations. 368
Although the performance of models with the F2 set was the best for all cases, the 369
experiments performed on the F1 set had also good results. Table 3 compares the 370
prediction accuracy of the proposed method (by averaging the accuracy for both 371
genders) with existing methods, which have been evaluated on the ADNI dataset and 372
other data sources. Note that we only showed the most significant results of those 373
studies, mainly focusing on MRI and its combination with other features. 374
Table 3. Comparison of methods performances focused on subject classification (%).
Method AD vs HC MCI vs HC cAD vs sMCI Data used
ACC SEN SPE ACC SEN SPE ACC SEN SPE
Kloeppel et al. [30] 95.0 95.0 95.0 - - - - - - MRI
Vemuri et al. [3] - 86.0 86.0 - - - - - - MRI
- 88.0 90.0 - - - - - - MRI,age,gender
- 86.0 92.0 - - - - - - MRI,age,gender,APOE
Cui et al. [19] - - - - - - 67.13 96.43 48.28 NM,CSF,MRI
- - - - - - 62.24 92.86 42.53 NM,MRI
- - - - - - 62.24 57.14 65.52 MRI
Cuingnet et al. [31] - 81.0 95.0 - - - - 57.0 78.0 MRI
Zhang et al. [25]* 93.3 - - 83.2 - - 73.9 68.6 73.6 MRI,PET,CSF
Suk et al. [28] 95.9 - - 85.0 - - 75.8 - - MRI,PET
Jie et al. [26] 95.03 94.90 95.00 79.27 85.86 66.64 68.94 64.65 71.79 MRI,FDG-PET
Gaser et al. [22] - - - - - - 75.00 71.00 84.00 MRI-based age
Spulber et al. [23] 88.4 86.1 90.4 - - - 67.7 69.6 66.8 MRI-based index
Aguilar et al. [24] - 92.0 75.0 - - - - 92.0 47.0 MRI-based index
Liu et al. [27] 94.37 94.71 94.04 78.8 84.85 67.06 67.83 64.88 70.0 MRI,PET
Suk et al. [29] 92.38 91.54 94.56 84.24 99.58 53.79 72.42 36.70 90.98 MRI
93.35 94.65 95.22 85.67 95.37 65.87 75.92 48.04 95.23 MRI,PET
*Proposed method (F1) 89.22 90.73 86.85 77.08 95.53 26.98 70.30 64.26 75.14 MRI-based residuals, age
*Proposed method (F2) 94.11 96.54 90.28 83.77 93.55 57.55 76.72 70.77 81.62 MRI-based residuals, age, MMSE,CDRGLOBAL
* Results of this method correspond to the average of performance recorded for men and women. MRI, Magnetic Resonance
Imaging-based features; CSF; Cerebral Spinal Fluid-based biomarkers; NM: Neuro-psychological measures; PET, Positron
Emission Tomography-based features; FDG-PET, [18F]fluorodeoxyglucose uptake measured in PET; MRI-based age,
individual estimated age computed from MRI images; MRI-based index, individual severity index computed from MRI
images; MMSE, Mini-Mental Clinical Dementia Rating; CDRGLOBAL, CDR Global Score.
Early prediction of subject diagnostics based on ROI residuals 375
The table in S5 Table shows the performance of models built for early prediction of 376
disease progression. As in previous results, although models built with the F2 377
configuration have obtained slightly better accuracies than the ones built on the F1 378
configuration, both performances are very satisfactory. Table 4 shows the average 379
number of years this method leads in predicting the subject diagnosis. This 380
advancement in the prediction was only possible in subjects whose dxage (diagnostic at 381
each visitation) was different from their dxlast diagnosis (last known diagnostic). 382
Therefore, only these subjects were taken into account and some age groups lack enough 383
data to be shown in this table. For females, the prediction of conversion from MCI to 384
AD was up to 1.9 years earlier (60–64 age group); and for males, up to 1.73 years earlier 385
(80–84 age group). However, the greatest lead was obtained in the early prediction from 386
HC to MCI in females, this being 2.89 years earlier. 387
Along with the time advancement in the prediction, Table 4 also shows the average 388
prediction accuracy for that differential diagnostic stratified by gender and age group. 389
Note that differences between accuracies of Tables 3 and 4 are due to the last one 390
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included a few samples, namely those that fit the conditions of five-year age group 391
stratification and whose last known diagnostic differs from the diagnostic at the time of 392
the test in the given age group. 393
Table 4. Last known diagnostic prediction advancement
Advancement for early prediction in years
Experiment 60-64 yrs. 65-69 yrs. 70-74 yrs. 75-79 yrs. 80-84 yrs. 85-89 yrs.
Females
AD vs HC 1.772 (85.73) 1.596(86.05) 1.335(86.79) 1.745(88.93) 1.523(90.21) 1.245(89.67)
MCI vs HC N/A N/A 2.888(74.42) 2.071(76.08) 2.381(78.40) N/A
AD vs MCI 1.982(69.23) 1.539(70.04) 1.307(69.55) 1.751(71.37) 1.509(72.41) 1.433(71.28)
Males
AD vs HC 1.232(84.27) 1.801(85.30) 1.667(86.91) 1.327(87.75) 1.775(89.44) 1.006(89.52)
MCI vs HC 1.257(72.47) N/A 1.739(77.29) 2.529(78.32) 2.686(78.59) 1.439(79.81)
AD vs MCI 1.448(68.95) 1.697(69.44) 1.679(70.22) 1.372(71.18) 1.733(73.46) 1.011(73.06)
N/A means there are not enough samples in the age interval for binary classification. (ACC) represents the prediction accuracy of F2 method in %
Discussion and Conclusions 394
This study has presented a framework for building ageing-associated null models from 395
longitudinal MRI-based biomarkers, as well as subject classification and early diagnosis 396
from residuals calculated through these null models. 397
Analysis of CSF biomarkers distributions allowed us to confirm the cut-offs values 398
established by [18] and to establish criteria for CSF profiling. We found subjects 399
clinically diagnosed as CN at baseline with abnormal CSF profile, which is consistent 400
with previous studies where the presence of possible AD pathology has been found in 401
ADNI control subjects [18, 51,52]. These findings may be because ADNI subject 402
diagnosis is made independently of the CSF biomarkers values (see S1 Appendix). 403
We modelled the longitudinal change of an extensive set of MRI-based biomarkers 404
obtained from cortical and subcortical regions. Studies have shown that early diagnosis 405
methods using the whole brain or the whole cortex reached higher specificity (over 90%) 406
than those based on the specific regions like the hippocampus (from 63% to 407
84%) [31,53,54]. LME modelling allowed to classify biomarkers as variant or 408
quasi-variant ROIs, and to build null models for ageing-related changes in men and 409
women. As in previous studies [6, 8, 9], our results (see Figure in S6 Fig) show that part 410
of these changes occur in brain areas related with AD. We found reductions for most 411
thickness and volume biomarkers of cortical regions [8] in both genders. Similar changes 412
were also found in subcortical regions including the greater atrophy in the hippocampus 413
and regions of the corpus callosum. 414
Null models were carried out by making assumptions of correlation between the 415
y-intercepts values (at basal stage) of variant and quasi-variant ROIs, where the first 416
ones were explained in function of last ones using PLSR. By using these null models and 417
LME   coefficients, we calculated residuals, which were established as differences 418
between the observed ROIs and age-related inferred ROIs. These residuals were 419
computed for new cohort of HC, MCI and subjects; and used for training and testing 420
SVM models to address subject classification and early disease prediction. 421
As of the date of this study, we were unable to find studies where ageing-related null 422
models and residuals-based classifiers were applied to early diagnosis. The performance 423
obtained in all experiments suggests that the proposed method of obtaining the ROI 424
residuals and their use to train SVM predictors is useful to support the early diagnosis 425
problem, the fundamental challenge in AD research. LME modelling of MRI-based 426
biomarkers was only applied by fitting age and years of education, but future work 427
could assess the impact of different available feature types such as other functional 428
PLOS 12/20
neuroimaging biomarkers, genetic factors, biological markers and other clinical and 429
neuropsychological assessment. 430
The main contributions of the residual-based classifier presented in this paper are: 431
(a) From a longitudinal study of 5 years follow-up, the ability to predict the future 432
diagnostic of the subjects up to 2.88 years earlier than the standard clinical procedure. 433
(b) Use of relatively common clinical tests such as MRI and neuropsychological tests, as 434
opposed to methods that rely on more expensive or invasive tests such as PET-based, 435
CSF-based and Genotype-based biomarkers. (c) HC vs AD: highest sensitivity among 436
the state of the art methods; a classification accuracy of 94%, higher than all MRI-only 437
methods except for [30]. (d) sMCI vs cAD: highest classification accuracy among the 438
state of the art methods. (e) In most experiments, the sensitivity (the ability of a 439
predictor to correctly classify a subject as ’diseased’) was higher than the specificity 440
(the ability of predictor to correctly classify a subject as ’disease-free’). This may be due 441
to the fact that ADNI clinical diagnosis is based on neuro-psychological tests, but 442
neurodegeneration occurs many years before the onset of clinical symptoms. Possibly, 443
residual-based SVM predictors may determine that subjects are into early stages of 444
disease (MCI and prodromal AD) but this finding is not consistent with clinical 445
diagnosis because the subject does not yet present clinical symptoms. Abnormalities of 446
CSF profile observed on several subjects diagnosed as HC and MCI (see Figure in S3 447
Fig) may support this hypothesis. 448
The use of MMSE and CDRGLOBAL tests (F2 method) yields significantly better 449
results than using the residuals alone (F1 method). These are two of the most common 450
neuropsychological tests routinely applied to patients in the primary clinical practice. 451
However this should not be seen as a mere contribution of MMSE and CDRGLOBAL, 452
as these tests on their own have several limitations such as relatively low specificity and 453
reliability. However, they complement and enhance the present method here without 454
adding a significant cost or invasive clinical tests. 455
Despite promising results, there are several limitations to our study. Firstly, data 456
used here correspond to research participants, who meet the inclusion and exclusion 457
criteria established by ADNI, and thus are not from general population. Secondly, the 458
available observations of CSF biomarkers do not correspond in number or time points 459
with the available MRI-based observations. In most cases we had just CSF values at the 460
baseline stage, so it is impossible to track the reliability of CSF profile at the final 461
stages. Due to this, it is important to emphasize that subject classifications based on 462
CSF profile are applicable to the ADNI study subjects, but not necessarily to 463
individuals in other settings. Thirdly, like CSF biomarkers, we had substantial missing 464
data for MRI-based biomarkers measured for 46 HC subjects during the 60-month 465
follow-up period. Although a LME approach can handle missing time points within 466
individuals, this issue may limit our ability to make inferences about the age-related 467
changes in these biomarkers. Finally, the proposed methodology to obtain a null model 468
of healthy elderly people is still at the early stages of the development and evaluation 469
process, it is necessary to test the null model in populations different from those used in 470
model development. 471
Supporting Information 472
S1 Appendix. Brief Data and Methods Description. 473
(PDF) 474
S1 Fig. Example of LME modelling for hypothetical variant (vr) and 475
quasi-variant(qvr) ROIs. HC and AD are hypothetical subjects. P1, P2 and P3 are 476
observations of each ROI y at three different ages (a1, a2 and a3). Black lines, healthy 477
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population regression line calculated from LME. yˆ0, vertical y-intercept value of healthy 478
population. Blue and red lines, individual regression lines estimated by assuming both 479
as healthful. Points Pˆ1, Pˆ2 and Pˆ3, inferred yˆ’s for the three ages.yˆHC0 and yˆAD0 , the 480
subject-specific y-intercepts estimated for HC and AD subjects, respectively. yˆHC0 and 481
yˆAD0 of vr ROI are inferred from the yˆHC0 and yˆAD0 of qvr ROI through PLSR model. 482
 a, slope or rate change of standard deviation of ROI per unit of age. ✏HC1, ✏HC2, 483
✏HC3, ✏AD1, ✏AD2 and ✏AD3, the residuals of each observation with respect to the 484
estimated individual regression lines. 485
(PDF) 486
S2 Fig. Distribution of CSF-based biomarkers at follow-up 84 months. (a) 487
CSF-A . (b) CSF-⌧ . 4: 8 of 113 CN subjects were converted to MCI and 1 CN subject 488
was converted to AD.  : 88 of 94 LMCI were converted to AD and 5 were re-converted 489
to HC at follow-up visits. Dotted vertical lines within each diagnosis are the determined 490
cutoff concentrations. Figure shows us that several subjects with abnormal CSF profile 491
classified as CN by ADNI at baseline clinical assessment were converted to MCI or AD 492
(triangle dots) along time. Likewise, some subjects classified like ’LMCI’ by ADNI were 493
converted to AD later (open circles). 494
(PDF) 495
S3 Fig. CSF-A  vs. CSF-⌧ concentration available at last subject’s 496
observations. Dots represent the last CSF biomarker measured for subjects available 497
at April, 2015. Vertical and horizontal dashed lines split normal CSF-profile from 498
abnormal profile. Null models for characterization of healthy brain structures were built 499
from samples labelled with blue dots. 500
(PDF) 501
S4 Fig. Boxplot of trajectory of left hippocampal volume for 502
normal-HCcsf subjects. High between-subject variability is evident, e.g., by 503
comparing subject 099 S 0533 with subject 133 S 0488. Likewise, there is a strong 504
indication of gender effect over hippocampal volume, female volumes are less than the 505
male ones. Note that we standarized every MRI-based biomarker to have zero mean and 506
unit variance. 507
(PDF) 508
S5 Fig. Examples of variant and quasi-variant ROIs per normal-HCcsf 509
subjects stratified by gender. (a) Left hippocampal volume classified as variant 510
(vr) ROI; where the slope of trajectories is not close to zero. (b) Left caudate volume 511
classified as quasi-variant (qvr) ROI; where the slope of trajectories is close to zero. 512
Note that for both regions, the y-intercept values vary between subjects, but the slope 513
value of each ROI is the same for all subjects. 514
(PDF) 515
S6 Fig. Characterization of ageing-based variant (vr) and quasi-variant 516
(qvr) ROIs.(a) Males. (b) Females. Biomarkers are coloured according their change 517
type: blue for vr regions and red for the qvr ones. The size of biomarkers with 518
significant P -value  0.05 are bigger than the not significant. Dotted vertical lines 519
separate the increased biomarkers (positive beta values) from the reduced ones 520
(negative beta values). ROIs are represented according to their location into brain 521
hemisphere (lh:left, rh: right or bilateral). SV: Subcortical Volume, CV: Cortical 522
volume, SA: Surface Area. lh: left hemisphere. rh: right hemisphere. 523
(PDF) 524
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S1 Table. Statistical descriptors of studied ADNI cohort at baseline. 525
(PDF) 526
S2 Table. Statistical descriptors of males used to build the SVM. 527
(PDF) 528
S3 Table. Statistical descriptors of females used to build the SVM. 529
(PDF) 530
S4 Table. Performances of classification for current diagnostic. 531
(PDF) 532
S5 Table. Performances of classification for last known diagnostic. 533
(PDF) 534
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